abstract |
The present invention relates to the use of NKG2A-neutralizing agents and PD-1 neutralizing agents to treat cancers, notably cancers that are not characterized by DNA mismatch repair deficiency. Provided are methods of treatment of a cancer, as well as compositions and kits useful for treating a cancer that is not characterized by DNA mismatch repair deficiency. |